新型MET外显子14跳跃型初治肺腺癌对克唑替尼呈现原发性耐药。 - Suppr

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.

作者信息

Jiang Wenjuan, Yang Nong, Zhang Yongchang

机构信息

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China.

出版信息

J Thorac Oncol. 2018 Jul;13(7):e124-e126. doi: 10.1016/j.jtho.2018.02.030.

DOI:10.1016/j.jtho.2018.02.030

PMID:29935852

Abstract

摘要

相似文献

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.新型MET外显子14跳跃型初治肺腺癌对克唑替尼呈现原发性耐药。

J Thorac Oncol. 2018 Jul;13(7):e124-e126. doi: 10.1016/j.jtho.2018.02.030.

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制

J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.

Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.通过下一代测序在肺腺癌中鉴定出一种新型的对克唑替尼敏感的MET-ATXN7L1基因融合变体。

Ann Oncol. 2018 Dec 1;29(12):2392-2393. doi: 10.1093/annonc/mdy455.

Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.在对克唑替尼治疗敏感的肺腺癌中鉴定出一种新型MET外显子14跳跃变异体

J Thorac Oncol. 2021 Mar;16(3):e17-e19. doi: 10.1016/j.jtho.2020.11.014.

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.MET外显子14跳跃的晚期肺腺癌对克唑替尼的获得性耐药

Lung Cancer. 2017 Nov;113:69-71. doi: 10.1016/j.lungcan.2017.09.006. Epub 2017 Sep 15.

Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.基于 DNA 的高度精确检测和治疗肺癌中 MET 外显子 14 跳跃突变的结果。

Lung Cancer. 2020 Feb;140:46-54. doi: 10.1016/j.lungcan.2019.11.010. Epub 2019 Nov 18.

Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.肺腺癌中 MET c-Cbl 结合位点突变患者对克唑替尼的临床反应和耐药性的出现。

Lung Cancer. 2020 Jan;139:165-168. doi: 10.1016/j.lungcan.2019.11.020. Epub 2019 Nov 26.

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体

J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.

Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.携带有间充质-上皮转化因子外显子 14 跳跃突变的肺腺癌患者对克唑替尼和卡博替尼的反应：一例报告。

Medicine (Baltimore). 2021 Jan 29;100(4):e24300. doi: 10.1097/MD.0000000000024300.

A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.携 MET c. 3028 + 2 T >A 变异的肺腺癌患者对克唑替尼治疗敏感。

Invest New Drugs. 2022 Aug;40(4):870-873. doi: 10.1007/s10637-022-01252-4. Epub 2022 May 12.

引用本文的文献

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study.MET抑制剂治疗的携带MET扩增或MET外显子14跳跃突变的晚期非小细胞肺癌患者的预后及并发基因组改变：一项回顾性研究

Front Oncol. 2021 Jun 24;11:649766. doi: 10.3389/fonc.2021.649766. eCollection 2021.

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.靶向HGF/MET轴在癌症治疗中的应用：耐药性挑战与改进机遇

Front Cell Dev Biol. 2020 May 6;8:152. doi: 10.3389/fcell.2020.00152. eCollection 2020.

Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.MET 外显子 14 跳跃突变的非小细胞肺癌患者的管理。

Curr Treat Options Oncol. 2020 Apr 18;21(4):33. doi: 10.1007/s11864-020-0723-5.

Brain Metastases from Lung Cancer: Is MET an Actionable Target?肺癌脑转移：MET是一个可靶向治疗的靶点吗？

Cancers (Basel). 2019 Feb 26;11(3):271. doi: 10.3390/cancers11030271.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献